FDA Approves Sodium Acetate Application ANDA220274 by Extrovis
The FDA has approved the application ANDA220274 for Sodium Acetate submitted by Extrovis.
Asset / Drug
Drug and asset intelligence for Extrovis with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.